Search research articles
Contact Us
Filters
Showing results (61-70 of 90) with videos related to
Page
of 9
Sort By:
American Journal of Hematology
|
May 31, 2016
Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation
Dipenkumar Modi, Hyejeong Jang, Seongho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2006
Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model
Ursula Reusch, Magesh Sundaram, Pamela A Davol, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 14, 2015
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Muthu Veeraputhiran, Tania Jain, Abhinav Deol, et al.
Journal of Clinical Apheresis
|
April 5, 2014
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant
Muthu Veeraputhiran, Tania Jain, Simon Cronin, et al.
Cardiovascular Research
|
April 23, 2010
Effect of disruption of Akt-1 of lin(-)c-kit(+) stem cells on myocardial performance in infarcted heart
Andy Tseng, Joan Stabila, Beth McGonnigal, et al.
Oncoimmunology
|
September 17, 2020
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
Lawrence G Lum, Archana Thakur, Minsig Choi, et al.
Journal for Immunotherapy of Cancer
|
January 28, 2025
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, et al.
Journal for Immunotherapy of Cancer
|
June 12, 2021
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer
Lawrence G Lum, Zaid Al-Kadhimi, Abhinav Deol, et al.
Oncotarget
|
January 13, 2016
Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal
Prahlad Parajuli, Rohit Anand, Chandramouli Mandalaparty, et al.
Oncogene
|
February 18, 2022
LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
Guilin Qiao, Lyonell B Kone, Evan H Phillips, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 90) with videos related to
Sort By:
Page
of 9
American Journal of Hematology
|
May 31, 2016
Incidence, etiology, and outcome of pleural effusions in allogeneic hematopoietic stem cell transplantation
Dipenkumar Modi, Hyejeong Jang, Seongho Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 7, 2006
Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model
Ursula Reusch, Magesh Sundaram, Pamela A Davol, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 14, 2015
BEAM Conditioning Regimen Has Higher Toxicity Compared With High-Dose Melphalan for Salvage Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma
Muthu Veeraputhiran, Tania Jain, Abhinav Deol, et al.
Journal of Clinical Apheresis
|
April 5, 2014
Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant
Muthu Veeraputhiran, Tania Jain, Simon Cronin, et al.
Cardiovascular Research
|
April 23, 2010
Effect of disruption of Akt-1 of lin(-)c-kit(+) stem cells on myocardial performance in infarcted heart
Andy Tseng, Joan Stabila, Beth McGonnigal, et al.
Oncoimmunology
|
September 17, 2020
Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients
Lawrence G Lum, Archana Thakur, Minsig Choi, et al.
Journal for Immunotherapy of Cancer
|
January 28, 2025
Rapamycin-resistant polyclonal Th1/Tc1 cell therapy (RAPA-201) safely induces disease remissions in relapsed, refractory multiple myeloma
Binod Dhakal, Parameswaran Hari, Saurabh Chhabra, et al.
Journal for Immunotherapy of Cancer
|
June 12, 2021
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0-2+) metastatic breast cancer
Lawrence G Lum, Zaid Al-Kadhimi, Abhinav Deol, et al.
Oncotarget
|
January 13, 2016
Preferential expression of functional IL-17R in glioma stem cells: potential role in self-renewal
Prahlad Parajuli, Rohit Anand, Chandramouli Mandalaparty, et al.
Oncogene
|
February 18, 2022
LIGHT enhanced bispecific antibody armed T-cells to treat immunotherapy resistant colon cancer
Guilin Qiao, Lyonell B Kone, Evan H Phillips, et al.
Page
of 9